Aethlon Medical (AEMD) investor relations material

Executive summary

• Advanced to the final cohort of the Australian oncology trial for the Hemopurifier platform, dosing the first participant and aiming to complete treatments and follow-up by end of 2026 or early 2027.

• Achieved clinical, research, and intellectual property milestones, with ongoing expansion into additional disease areas through preclinical research and collaborations.

• Preliminary biomarker data from initial cohorts of the oncology trial show encouraging and more consistent results, supporting continued evaluation.

• Manuscript on Long COVID and extracellular vesicles accepted for publication, highlighting exploratory research and potential new indications.

• Continued disciplined cost control and resource management to support clinical and research activities.

Financial highlights

• Cash and cash equivalents totaled $4,933,579 as of June 30, 2026, with $4 million raised post-quarter via public offering, supporting at least 12 months of operations.

• Operating expenses for Q2 2026 decreased 11.9% year-over-year to $1,579,202, mainly due to lower professional fees and reduced G&A and preclinical research costs.

• Operating loss narrowed to $1,579,202 from $1,792,390 in the prior-year quarter.

• Net loss attributable to common stockholders was $1,547,912, compared to $1,761,858 a year earlier; basic and diluted net loss per share was $4.02 versus $42.42 year-over-year, reflecting a significant increase in shares outstanding.

• Net cash used in operating activities was $1.9 million, up from $1.7 million in the prior year, mainly due to changes in working capital.

Outlook and guidance

• Cash resources, including recent financing, are expected to fund operations for at least the next 12 months based on current plans.

• Goal to complete all Hemopurifier treatments and follow-up for the oncology trial by end of 2026, with subsequent data analysis and regulatory discussions.

• Exploring further clinical development paths for Hemopurifier in long COVID and other diseases, pending discussions with academic and regulatory bodies.

• Additional capital will likely be required to advance clinical development beyond the next twelve months, with future needs dependent on trial progress, regulatory activities, and manufacturing.